LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

Search

Adaptive Biotechnologies Corp

Затворен

12.95 1.25

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

12.58

Максимум

12.98

Ключови измерители

By Trading Economics

Приходи

4.2M

-26M

Продажби

6.4M

59M

Марж на печалбата

-43.467

Служители

619

EBITDA

11M

-18M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+7.42% upside

Дивиденти

By Dow Jones

Следващи печалби

6.11.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

272M

1.9B

Предишно отваряне

11.7

Предишно затваряне

12.95

Техническа оценка

By Trading Central

Увереност

Very Strong Bullish Evidence

Adaptive Biotechnologies Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

27.08.2025 г., 22:51 ч. UTC

Печалби

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

27.08.2025 г., 23:57 ч. UTC

Печалби

Trip.com Group 1H Rev $4.01B

27.08.2025 г., 23:57 ч. UTC

Печалби

Trip.com Group 1H Adj EPS $1.84

27.08.2025 г., 23:57 ч. UTC

Печалби

Trip.com Group 1H EPS $1.82

27.08.2025 г., 23:50 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

27.08.2025 г., 23:39 ч. UTC

Печалби

Correction to Nvidia Earnings Article -- WSJ

27.08.2025 г., 22:59 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

27.08.2025 г., 22:59 ч. UTC

Пазарно говорене

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

27.08.2025 г., 22:58 ч. UTC

Печалби

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

27.08.2025 г., 22:57 ч. UTC

Печалби

South32 FY Free Cash Flow $192 Million

27.08.2025 г., 22:56 ч. UTC

Печалби

South32 FY Total Capital Expenditure $1.35 Billion

27.08.2025 г., 22:56 ч. UTC

Печалби

South32 FY Capital Expenditure $963 Million, Excluding EAIs

27.08.2025 г., 22:55 ч. UTC

Печалби

South32 Net Cash $123 Million at June 30

27.08.2025 г., 22:54 ч. UTC

Печалби

South32: Focused on Maintaining Strong Operating Momentum

27.08.2025 г., 22:53 ч. UTC

Печалби

South32: $144 Million Remains to be Returned to Shareholders Under Program

27.08.2025 г., 22:53 ч. UTC

Печалби

South32 Extends Capital Management Program for 12 Months

27.08.2025 г., 22:52 ч. UTC

Печалби

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

27.08.2025 г., 22:51 ч. UTC

Печалби

South32 FY Revenue $5.78 Billion, Up 17% On-Year

27.08.2025 г., 22:51 ч. UTC

Печалби

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

27.08.2025 г., 22:50 ч. UTC

Печалби

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

27.08.2025 г., 22:50 ч. UTC

Печалби

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

27.08.2025 г., 22:45 ч. UTC

Печалби

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

27.08.2025 г., 22:44 ч. UTC

Печалби

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

27.08.2025 г., 22:44 ч. UTC

Печалби

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

27.08.2025 г., 22:43 ч. UTC

Печалби

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

27.08.2025 г., 22:43 ч. UTC

Печалби

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

27.08.2025 г., 22:42 ч. UTC

Печалби

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

27.08.2025 г., 22:42 ч. UTC

Печалби

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

27.08.2025 г., 22:40 ч. UTC

Печалби

Sandfire Resources Net Debt $123 Million at June 30

27.08.2025 г., 22:40 ч. UTC

Печалби

Sandfire Resources FY Underlying Ebitda $527.7 Million

Сравнение с други в отрасъла

Ценова промяна

Adaptive Biotechnologies Corp Прогноза

Ценова цел

By TipRanks

7.42% нагоре

12-месечна прогноза

Среден 13.75 USD  7.42%

Висок 15 USD

Нисък 11 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Adaptive Biotechnologies Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

7 ratings

6

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

8.81 / 10.18Подкрепа & съпротива

Краткосрочен план

Very Strong Bullish Evidence

Средносрочен план

Strong Bullish Evidence

Дългосрочен план

Weak Bullish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.